Asia Spotlight: New Strategies Needed As China Shakes Up Drug Classes?
Executive Summary
In a fundamental shakeup of chemical drug classifications in China, foreign imported products are now in a class of their own while domestic drugs will be considered generics unless they are NCEs or have new formulations or indications. The changes are set to change the competitive landscape in profound ways, industry observers predict.
You may also be interested in...
Revised China Drug Regulation Sets Back IPR Protection – Experts
Long-awaited revised draft of China’s main drug registration regulation has legal experts wondering whether the China FDA is opening the flood gates to generic copies of new drugs due to a loosening of patent linkage provisions. Lack of provisions on review time limits and multiregional trials also disappoint some, although new OTC moves may be positive.
Revised China Drug Regulation Sets Back IPR Protection – Experts
Long-awaited revised draft of China’s main drug registration regulation has legal experts wondering whether the China FDA is opening the flood gates to generic copies of new drugs due to a loosening of patent linkage provisions. Lack of provisions on review time limits and multiregional trials also disappoint some, although new OTC moves may be positive.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.